All that glitters is not gold: The need to consider desirable and undesirable immune aspects of oncolytic virus therapy

OncoImmunology

Volumn 5, Issue 1, 2016, Pages

  Clements, Derek R ^a   Kim, Youra ^a   Gujar, Shashi A ^a,b   Lee, Patrick W K ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b IWK HEALTH CENTRE   (Canada)

Author keywords

Antitumor immunity; Immunosuppression; MDSCs; Oncolytic virus; Reovirus; Tumor microenvironment

Indexed keywords

ARTICLE; CANCER GROWTH; CANCER THERAPY; CELL PROLIFERATION; CYTOKINE PRODUCTION; CYTOTOXICITY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; ONCOLYTIC VIROTHERAPY; T CELL DEPLETION;

EID: 84954453434     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1057674     Document Type: Article

References (10)

1. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer 2014; 14:559-67; PMID:24990523; http://dx. doi. org/ 10. 1038/nrc3770
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx. doi. org/10. 1038/ nrc3239
3. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14:1014-22; PMID:24048123; http:// dx. doi. org/10. 1038/ni. 2703
4. Ilkow CS, Marguerie M, Batenchuk C, Mayer J, Ben Neriah D, Cousineau S, Falls T, Jennings VA, Boileau M, Bellamy D et al. Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nat Med 2015; 21:530-6; PMID:25894825; http://dx. doi. org/ 10. 1038/nm. 3848
5. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx. doi. org/10. 1038/nri3175
6. Fortin C, Huang X, Yang Y. NK cell response to vaccinia virus is regulated by myeloid-derived suppressor cells. J Immunol 2012; 189:1843-9; PMID:22798671; http://dx. doi. org/10. 4049/ jimmunol. 1200584
7. Clements DR, Sterea AM, Kim Y, Helson E, Dean CA, Nunokawa A, Coyle KM, Sharif T, Marcato P, Gujar SA et al. Newly recruited CD11b+, GR-1+, Ly6Chigh myeloid cells augment tumor-associated immunosuppression immediately following the therapeutic administration of oncolytic reovirus. J Immunol 2015; 194:4397-412; PMID:25825443; http://dx. doi. org/10. 4049/jimmunol. 1402132
8. DeWeerdt S. Bacteriology: A caring culture. Nature 2013; 504:S4-5; PMID:24352362; http://dx. doi. org/ 10. 1038/504S4a
9. Goh C, Narayanan S, Hahn YS. Myeloid-derived suppressor cells: The dark knight or the joker in viral infections? Immunol Rev 2013; 255:210-21; PMID:23947357; http://dx. doi. org/10. 1111/ imr. 12084
10. Gujar SA, Clements D, Dielschneider R, Helson E, Marcato P, Lee PW. Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms. Br J Cancer 2014; 110:83-93; PMID:24281006; http://dx. doi. org/ 10. 1038/bjc. 2013. 695